MX379846B - Derivados de 4-bencil y 4-benzoil piperidina sustituidos. - Google Patents

Derivados de 4-bencil y 4-benzoil piperidina sustituidos.

Info

Publication number
MX379846B
MX379846B MX2017016370A MX2017016370A MX379846B MX 379846 B MX379846 B MX 379846B MX 2017016370 A MX2017016370 A MX 2017016370A MX 2017016370 A MX2017016370 A MX 2017016370A MX 379846 B MX379846 B MX 379846B
Authority
MX
Mexico
Prior art keywords
substituted
benzyl
substituted piperidine
piperidine derivatives
piperidine compounds
Prior art date
Application number
MX2017016370A
Other languages
English (en)
Other versions
MX2017016370A (es
Inventor
Bruce D Dorsey
Craig A Zificsak
Dimitar B Gotchev
Linda Weinberg
Nadine C Becknell
Reddeppa Reddy Dandu
Robert L Hudkins
Original Assignee
89Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 89Bio Ltd filed Critical 89Bio Ltd
Publication of MX2017016370A publication Critical patent/MX2017016370A/es
Publication of MX379846B publication Critical patent/MX379846B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen en la presente compuestos de piperidina 1,4-sustituidos de acuerdo con la fórmula I que tienen actividad demostrada como inhibidores de la sintasa del ácido graso. También se describen en la presente composiciones farmacéuticas que contiene los compuestos de piperidina 1,4-sustituidos descritos. También se describen métodos para tratar enfermedades mediadas por la sintasa del ácido graso, al administrar uno o más de los compuestos o formulaciones farmacéuticas descritas en la presente. También se describen en la presente métodos para sintetizar los compuestos de piperidina 1,4-sustituidos descritos e intermediarios sintéticos útiles en aquellas síntesis.
MX2017016370A 2015-06-18 2016-06-17 Derivados de 4-bencil y 4-benzoil piperidina sustituidos. MX379846B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562181391P 2015-06-18 2015-06-18
PCT/US2016/037980 WO2016205590A1 (en) 2015-06-18 2016-06-17 Substituted 4-benzyl and 4-benzoyl piperidine derivatives

Publications (2)

Publication Number Publication Date
MX2017016370A MX2017016370A (es) 2018-04-11
MX379846B true MX379846B (es) 2025-03-11

Family

ID=56297117

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016370A MX379846B (es) 2015-06-18 2016-06-17 Derivados de 4-bencil y 4-benzoil piperidina sustituidos.

Country Status (8)

Country Link
US (3) US10919875B2 (es)
EP (1) EP3310773B1 (es)
JP (2) JP6986972B2 (es)
CA (1) CA3014432C (es)
ES (1) ES2849951T3 (es)
IL (1) IL256323B (es)
MX (1) MX379846B (es)
WO (1) WO2016205590A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191860T1 (hr) 2013-03-13 2019-12-27 Forma Therapeutics, Inc. Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
WO2016205633A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. 1, 4-substituted piperidine derivatives
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MX2020008894A (es) 2018-03-22 2020-10-12 Hoffmann La Roche Inhibidores de oxazin monoacilglicerol lipasa (magl).
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
CR20230115A (es) 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
EE200100323A (et) 1998-12-18 2002-08-15 Axys Pharmaceuticals, Inc. (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
WO2002014261A2 (en) * 2000-08-10 2002-02-21 Eli Lilly And Company 4-substituted d-glutamic acid derivatives for use as antibiotic
WO2003053975A1 (en) 2001-12-13 2003-07-03 Daiichi Suntory Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
US7399819B2 (en) 2002-09-17 2008-07-15 Chisso Corporation Silicon compound
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2005037198A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
EP1688420A4 (en) 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
KR20060129023A (ko) 2004-02-23 2006-12-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 헤테로환 화합물
DE602005027739D1 (de) 2004-06-30 2011-06-09 Janssen Pharmaceutica Nv Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
EP1976848A2 (en) 2005-12-21 2008-10-08 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
WO2007089634A2 (en) 2006-01-30 2007-08-09 Merck & Co., Inc. Inhibitors of fatty acid synthase (fas)
CA2652385A1 (en) 2006-06-08 2007-12-21 Eli Lilly And Company Novel mch receptor antagonists
US7625746B2 (en) 2006-07-24 2009-12-01 Nanosphere, Inc. Method of denaturing and fragmenting DNA or RNA using ultrasound
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
EP2114941B1 (en) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
JP2010518026A (ja) 2007-02-05 2010-05-27 ゼノン・ファーマシューティカルズ・インコーポレイテッド ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物
PE20090215A1 (es) 2007-05-09 2009-03-30 Novartis Ag Compuestos derivados de imidazopiridazinas como inhibidores de cinasa
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
JP2011521978A (ja) 2008-06-02 2011-07-28 ファスジェン， インコーポレイテッド 新規化合物、それを含む医薬組成物、およびこれらの使用方法
EP2318391A1 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic heterocycle derivatives as histamine h3 antagonists
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
KR101709492B1 (ko) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 신규한 소염제
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US8614238B2 (en) 2009-10-19 2013-12-24 Boehringer Ingelheim International Gmbh Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use
JP2013508461A (ja) 2009-10-27 2013-03-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011066211A1 (en) 2009-11-24 2011-06-03 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
SG10201907588XA (en) 2010-02-16 2019-09-27 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
EP2536411A4 (en) 2010-02-18 2013-08-07 Univ Princeton HEMMER OF THE METABOLISM OF LOW-CHAIN AND VERY LOW-FATTYED FATTY ACIDS AS AN ANTIVIRUS ACTIVE SUBSTANCES WITH A WIDE SPECTRUM
ES2509951T3 (es) 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
JP5794297B2 (ja) 2010-05-07 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９アゴニストとしてのピリダジノン
JP2013166700A (ja) 2010-06-02 2013-08-29 Dainippon Sumitomo Pharma Co Ltd 新規４，５−縮環ピリミジン誘導体
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 脂肪酸シンターゼ阻害剤
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
WO2012096928A2 (en) 2011-01-10 2012-07-19 Glaxosmithkline Llc Pyrimidinone derivatives as fatty acid synthase inhibitors
EP2683244B1 (en) 2011-03-08 2017-02-01 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
AR086042A1 (es) 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
US8859535B2 (en) * 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2013028445A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013028447A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013052716A1 (en) 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
US9580390B2 (en) 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
KR101415174B1 (ko) 2012-04-26 2014-07-04 (주) 메디프론디비티 신규한 벤조옥사졸계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
WO2014004863A2 (en) 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
EP2867233A1 (en) 2012-07-03 2015-05-06 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
JP6109934B2 (ja) 2012-07-03 2017-04-05 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脂質合成の複素環モジュレーター
JP2015526468A (ja) 2012-08-22 2015-09-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 新規なアザベンズイミダゾールヘキサヒドロフロ［３，２−ｂ］フラン誘導体
WO2014039769A1 (en) 2012-09-07 2014-03-13 Janssen Pharmaceutica Nv Imidazolin-5-one derivatives useful as fatty acid snthase (fasn) inhibitors for|the treatment of cancer
AR092211A1 (es) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung Derivados de hidropirrolopirrol
WO2014053568A1 (en) 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
MX2015006037A (es) 2012-11-16 2015-08-07 Merck Patent Gmbh Derivados de 3-aminociclopentancarboxamida.
HRP20191860T1 (hr) 2013-03-13 2019-12-27 Forma Therapeutics, Inc. Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ES2634875T3 (es) 2013-03-21 2017-09-29 Merck Patent Gmbh Derivados de piperazina como inhibidores de FASN
KR101524208B1 (ko) 2013-04-26 2015-05-29 한국화학연구원 벤조옥사졸 유도체, 이의 제조방법 및 이를 포함하는 의약 조성물
US9172428B2 (en) * 2013-06-28 2015-10-27 Intel Corporation Determining the spectral energy content of a data bus
CA2919552C (en) 2013-07-29 2022-03-15 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives
DE102013215035B3 (de) 2013-07-31 2014-11-06 Siemens Aktiengesellschaft Soft-Redundanzprotokoll
US9562035B2 (en) * 2013-12-03 2017-02-07 Janssen Pharmaceutica Nv Benzamide derivative useful as FASN inhibitors for the treatment of cancer
WO2016011019A1 (en) * 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
WO2016041201A1 (zh) * 2014-09-19 2016-03-24 上海创诺医药集团有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TW201629033A (zh) * 2014-10-08 2016-08-16 健生藥品公司 作為治療第二型糖尿病之ｇｐｒ４０促效劑的經取代苯并噻吩基衍生物
WO2016205633A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. 1, 4-substituted piperidine derivatives
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
JP6986872B2 (ja) 2017-06-23 2021-12-22 昭和電工株式会社 ウェハ支持台、化学気相成長装置、及び、ＳｉＣエピタキシャルウェハの製造方法

Also Published As

Publication number Publication date
US12441702B2 (en) 2025-10-14
IL256323A (en) 2018-02-28
IL256323B (en) 2020-09-30
EP3310773B1 (en) 2020-12-02
US20200031797A1 (en) 2020-01-30
JP7334211B2 (ja) 2023-08-28
EP3310773A1 (en) 2018-04-25
US10919875B2 (en) 2021-02-16
MX2017016370A (es) 2018-04-11
ES2849951T3 (es) 2021-08-24
WO2016205590A1 (en) 2016-12-22
US11878966B2 (en) 2024-01-23
CA3014432A1 (en) 2016-12-22
HK1252794A1 (en) 2019-06-06
JP6986972B2 (ja) 2021-12-22
JP2021121612A (ja) 2021-08-26
CA3014432C (en) 2024-05-07
US20240166625A1 (en) 2024-05-23
JP2018524318A (ja) 2018-08-30
US20220081411A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
PH12017502331A1 (en) 1,4-substituted piperidine derivatives
MX2017016370A (es) Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CY1122244T1 (el) Παραγωγα 2-υδροξυ-1-{4-[(4-φαινυλφαινυλ)καρβονυλ]πιπεραζιν-1-υλ}αιθαν-1-ονης και σχετικες ενωσεις ως αναστολεις συνθασης λιπαρου οξεος(fαsν) για την θεραπεια καρκινου
MX392586B (es) Derivados de la espiropiperidina.
MX381953B (es) Sales de derivados de piperazina obtenidas por adicion de acidos.
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX376054B (es) Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo.
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX388170B (es) Polimorfos de selinexor
CO2017004530A2 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX378591B (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
BR112017000584A2 (pt) inibidores da aldosterona sintase
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
TH174354A (th) สารต้าน-การอักเสบ และ สารกดระงับการผลิตเมลานิน
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors